Niacin and biosynthesis of PGD 2 by platelet COX-1 in mice and humans

Journal of Clinical Investigation

Volumn 122, Issue 4, 2012, Pages 1459-1468

  Song, Wen Liang ^a   Stubbe, Jane ^a,b   Ricciotti, Emanuela ^a   Alamuddin, Naji ^a   Ibrahim, Salam ^a   Crichton, Irene ^c   Prempeh, Maxwell ^d   Lawson, John A ^a   Wilensky, Robert L ^d   Rasmussen, Lars Melholt ^e   Puré, Ellen ^c   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c WISTAR INSTITUTE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN II; CLOPIDOGREL; CYCLOOXYGENASE 1; FIBRINOGEN; LAROPIPRANT; NICOTINIC ACID; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; HOMEOSTASIS; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; STIMULUS; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

6-KETOPROSTAGLANDIN F1 ALPHA; ADENOSINE DIPHOSPHATE; ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PLATELETS; CAROTID ARTERY THROMBOSIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN D2; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LDL; RECEPTORS, NICOTINIC; RECEPTORS, PROSTAGLANDIN; THROMBOXANE A2;

EID: 84859707908     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59262     Document Type: Article

References (57)

1. Urade Y, Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm. 2000;58:89-120.
2. Hirai H, et al. Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor. Biochem Biophys Res Commun. 2003;307(4):797-802. (Pubitemid 36871642)
3. Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2-3):187-194. (Pubitemid 36976174)
4. Sawyer N, et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002;137(8):1163-1172. (Pubitemid 36071733)
5. O'Sullivan S, Dahlen B, Dahlen SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol. 1996;98(2):421-432.
6. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003;111(4):743-749. (Pubitemid 36470243)
7. Awad JA, Morrow JD, Roberts LJ 2nd. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol. 1994;93(5):817-824. (Pubitemid 24154096)
8. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts LJ 2nd. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol. 1995;104(6):937-940.
9. Morrow JD, et al. Increased formation of thromboxane in vivo in humans with mastocytosis. J Invest Dermatol. 1999;113(1):93-97. (Pubitemid 29328165)
10. Matsuoka T, et al. Prostaglandin D2 as a mediator of allergic asthma. Science. 2000;287(5460):2013-2017.
11. Lai E, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther. 2008;83(6):840-847. (Pubitemid 351704913)
12. Van Hecken A, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol. 2007;63(2):135-141. (Pubitemid 46147054)
13. Hata AN, Zent R, Breyer MD, Breyer RM. Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003; 306(2):463-470. (Pubitemid 36886141)
14. Lewis RA, Holgate ST, Roberts LJ 2nd, Oates JA, Austen KF. Preferential generation of prostaglandin D2 by rat and human mast cells. Kroc Found Ser. 1981;14:239-254.
15. Qu WM, et al. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. Proc Natl Acad Sci U S A. 2006;103(47):17949-17954.
16. Dieter P, Scheibe R, Jakobsson PJ, Watanabe K, Kolada A, Kamionka S. Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. Biochem Biophys Res Commun. 2000;276(2):488-492.
17. Reddy ST, Herschman HR. Prostaglandin synthase- 1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J Biol Chem. 1997;272(6):3231-3237. (Pubitemid 27066813)
18. Song WL, et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem. 2008; 283(2):1179-1188.
19. Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978;16(3):373-388. (Pubitemid 9032516)
20. Oelz O, Oelz R, Knapp HR, Sweetman BJ, Oates JA. Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandins. 1977;13(2):225-234.
21. Bushfield M, McNicol A, MacIntyre DE. Inhibition of platelet-activating- factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. Biochem J. 1985;232(1):267-271. (Pubitemid 16199009)
22. Morrow JD, Awad JA, Oates JA, Roberts LJ 2nd. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98(5):812-815.
23. Morrow JD, Parsons WG 3rd, Roberts LJ 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38(2):263-274.
24. Hanson J, et al. Nicotinic acid- and monomethyl fumarate- induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910-2919.
25. Cheng K, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103(17):6682-6687.
26. Rajakariar R, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A. 2007; 104(52):20979-20984.
27. Grosser T, Yu Y, FitzGerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17-33.
28. Catella F, Healy D, Lawson JA, FitzGerald GA. 11- Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A. 1986;83(16):5861-5865. (Pubitemid 16000613)
29. Watanabe T, Narumiya S, Shimizu T, Hayaishi O. Characterization of the biosynthetic pathway of prostaglandin D2 in human platelet-rich plasma. J Biol Chem. 1982;257(24):14847-14853. (Pubitemid 13159578)
30. Whittle BJ, Hamid S, Lidbury P, Rosam AC. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets. Adv Exp Med Biol. 1985;192:109-125.
31. Monneret G, Li H, Vasilescu J, Rokach J, Powell WS. 15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol. 2002;168(7):3563-3569. (Pubitemid 34250426)
32. Capone ML, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109(12):1468-1471. (Pubitemid 38420172)
33. Heavey DJ, Barrow SE, Hickling NE, Ritter JM. Aspirin causes short-lived inhibition of bradykinin- stimulated prostacyclin production in man. Nature. 1985;318(6042):186-188. (Pubitemid 16192588)
34. Ritter JM, Cockcroft JR, Doktor HS, Beacham J, Barrow SE. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. Br J Clin Pharmacol. 1989;28(5):573-579. (Pubitemid 19273605)
35. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-2383. (Pubitemid 41713749)
36. Braden GA, Knapp HR, FitzGerald GA. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation. 1991; 84(2):679-685.
37. Cheng Y, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296(5567):539-541. (Pubitemid 34408674)
38. Cuff CA, et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest. 2001;108(7):1031-1040. (Pubitemid 32946077)
39. Yu Y, et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest. 2005;115(4):986-995. (Pubitemid 40489403)
40. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116(5):1391-1399.
41. Petri B, et al. von Willebrand factor promotes leukocyte extravasation. Blood. 2010;116(22):4712-4719.
42. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893. (Pubitemid 30062710)
43. Li G, et al. Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3. J Biol Chem. 2010;285(29):22605- 22618.
44. Walters RW, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009;119(5):1312-1321.
45. Stalker TJ, et al. Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo. J Thromb Haemost. 2009;7(11):1886-1896.
46. Zou Z, Chen H, Schmaier AA, Hynes RO, Kahn ML. Structure-function analysis reveals discrete beta3 integrin inside-out and outside-in signaling pathways in platelets. Blood. 2007;109(8):3284-3290. (Pubitemid 46572514)
47. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008; 153 suppl 1:S68-S75. (Pubitemid 351340990)
48. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest. 2010;121(3):1163-1173.
49. Rich JD, Cannon CP, Murphy SA, Qin J, Giugliano RP, Braunwald E. Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010; 56(17):1376-1385.
50. Francois H, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2(3):201-207.
51. Taylor AJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113-2122.
52. Taba Y, et al. Fluid shear stress induces lipocalin-type prostaglandin D(2) synthase expression in vascular endothelial cells. Circ Res. 2000;86(9):967-973. (Pubitemid 30324309)
53. Jacobson TA. A "hot" topic in dyslipidemia management - " how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin Proc. 2010;85(4):365-379.
54. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365(24):2250-2251.
55. Wang M, et al. Microsomal prostaglandin E synthase- 1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation. 2008;117(10):1302-1309. (Pubitemid 351365673)
56. Song WL, Lawson JA, Wang M, Zou H, FitzGerald GA. Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/ MS/MS method. Methods Enzymol. 2007;433:51-72.
57. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol. 2006;26(5):1137-1143. (Pubitemid 43732124)